'Crucially, Vutrisiran boosted the health outcomes of trial participants already using Tafamidis, a rival drug sold by Pfizer under the brand Vyndamax, which is currently the most common treatment option for ATTR-CM patients. Analysts have said Vutrisiran’s efficacy among this subgroup of patients would be key to justifying its use as a first-line therapy'
https://www.ft.com/content/cb16cf65-4b80-4027-9478-474d3b47e1e1